The G-CLB turned out to be the winner, achieving significantly more complete responses, minimal residual disease (MRD) negativity, and prolonging PFS in comparison to both CLB monotherapy and R-CLB combination; significant toxicity associated with obinutuzumab was predominantly infusion-related reactions and neutropenia, without the increased occurrence of serious infections [49]. This evidence concerns the gene CLYBL and Decreased total neutrophil count.